TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Enlivex ( (ENLV) ) has issued an announcement.
On December 4, 2025, Enlivex Therapeutics announced a virtual fireside chat scheduled for December 11, 2025, to discuss its digital asset strategy and the clinical development of Allocetra™. The company recently secured a $212 million private placement, which will support its strategic initiatives. This announcement highlights Enlivex’s efforts to strengthen its market position through innovative financial strategies and continued focus on addressing the significant healthcare burden of osteoarthritis.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a company operating in the biotechnology industry, focusing on the development of Allocetra™, a novel therapy for osteoarthritis, a prevalent joint disease. The company is also pioneering a digital asset treasury strategy centered on the RAIN token, aiming to provide investors with exposure to digital capital.
Average Trading Volume: 3,668,565
Technical Sentiment Signal: Sell
Current Market Cap: $23.19M
Learn more about ENLV stock on TipRanks’ Stock Analysis page.